Alexandra Pacurariu
Overview
Explore the profile of Alexandra Pacurariu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dernie F, Corby G, Robinson A, Bezer J, Mercade-Besora N, Griffier R, et al.
Pharmacoepidemiol Drug Saf
. 2024 Nov;
33(11):e70042.
PMID: 39532529
Purpose: The generation of representative disease phenotypes is important for ensuring the reliability of the findings of observational studies. The aim of this manuscript is to outline a reproducible framework...
2.
Du M, Dernie F, Catala M, Delmestri A, Man W, Brash J, et al.
Eur J Intern Med
. 2024 Aug;
130:106-117.
PMID: 39134452
Objective: Multiple treatment options are recommended for Systemic Lupus Erythematosus (SLE) by clinical guidelines. This study aimed to explore SLE treatment patterns as there is limited real-world data of SLE...
3.
Prilla S, Groeneveld S, Pacurariu A, Restrepo-Mendez M, Verpillat P, Torre C, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(5):1188-1197.
PMID: 38962830
Studies using real-world data (RWD) can complement evidence from clinical trials and fill evidence gaps during different stages of a medicine's lifecycle. This review presents the experience resulting from the...
4.
Hedenmalm K, Pacurariu A, Slattery J, Kurz X, Candore G, Flynn R
Drug Saf
. 2021 Jul;
44(9):973-985.
PMID: 34273099
Introduction: The analgesic metamizole, which has been withdrawn from the market in several countries due to the risk of agranulocytosis but is still available on the market in Germany and...
5.
Gini R, Sturkenboom M, Sultana J, Cave A, Landi A, Pacurariu A, et al.
Clin Pharmacol Ther
. 2020 Apr;
108(2):228-235.
PMID: 32243569
Although postmarketing studies conducted in population-based databases often contain information on patients in the order of millions, they can still be underpowered if outcomes or exposure of interest is rare,...
6.
Morales D, Pacurariu A, Slattery J, Kurz X
Br J Clin Pharmacol
. 2020 Feb;
86(7):1336-1345.
PMID: 32068906
Aims: Hydrochlorothiazide-induced photosensitivity may increase squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and lip cancer risk. The aim was to quantify these risks. Methods: Nested case-control studies using data...
7.
Flynn R, Hedenmalm K, Murray-Thomas T, Pacurariu A, Arlett P, Shepherd H, et al.
Clin Pharmacol Ther
. 2020 Jan;
107(4):957-965.
PMID: 31955404
This study measured the exposure to different categories of medicinal products discussed by the European Union (EU) Pharmacovigilance Risk Assessment Committee from September to November 2018 in four electronic primary...
8.
Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X
JAMA Neurol
. 2019 Apr;
76(7):827-833.
PMID: 31034074
Importance: Peripheral neuropathy has been associated with systemic fluoroquinolone exposure, but risk has been poorly quantified. Objective: To calculate relative and absolute risk estimates for the association of fluoroquinolone exposure...
9.
Morales D, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X
Clin Drug Investig
. 2019 Feb;
39(2):215.
PMID: 30725313
The article Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study, written by Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan...
10.
Morales D, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X
Clin Drug Investig
. 2018 Nov;
39(2):205-213.
PMID: 30465300
Background And Objective: Tendon rupture can result from fluoroquinolone exposure. The objective of this study was to quantify relative and absolute risk and determine how risk is affected by timing...